

Anthony Howell

List of Publications by Citations

Source: <https://exaly.com/author-pdf/5379169/anthony-howell-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

563
papers

41,054
citations

108
h-index

186
g-index

589
ext. papers

45,672
ext. citations

7.4
avg, IF

7.17
L-index

#	Paper	IF	Citations
563	Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. <i>Lancet, The</i> , 2005 , 365, 60-2	4.0	1805
562	Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. <i>Lancet Oncology, The</i> , 2008 , 9, 45-53	21.7	849
561	Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. <i>Cancer</i> , 2003 , 98, 1735-44	6.4	755
560	Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. <i>Lancet Oncology, The</i> , 2010 , 11, 1135-41	21.7	671
559	Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. <i>Cancer</i> , 2003 , 98, 1802-10	6.4	660
558	First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. <i>Lancet, The</i> , 2002 , 360, 817-24	4.0	611
557	Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. <i>Journal of Clinical Oncology</i> , 2002 , 20, 3396-403	2.2	557
556	Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. <i>Journal of Clinical Oncology</i> , 2011 , 29, 4273-8	2.2	549
555	Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. <i>Journal of Clinical Oncology</i> , 2010 , 28, 1829-34	2.2	547
554	Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. <i>Cancer Journal (Sudbury, Mass)</i> , 2001 , 7, 377-87	2.2	537
553	ATAC trial update. <i>Lancet, The</i> , 2005 , 365, 1225-1226	4.0	444
552	Dissociation between steroid receptor expression and cell proliferation in the human breast. <i>Cancer Research</i> , 1997 , 57, 4987-91	10.1	444
551	Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial. <i>Journal of the National Cancer Institute</i> , 2007 , 99, 272-82	9.7	437
550	Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. <i>Cancer</i> , 2001 , 91, 1191-200	6.4	433
549	Ketones and lactate "fuel" tumor growth and metastasis: Evidence that epithelial cancer cells use oxidative mitochondrial metabolism. <i>Cell Cycle</i> , 2010 , 9, 3506-14	4.7	429
548	Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. <i>Lancet, The</i> , 2014 , 383, 1041-8	4.0	428
547	The effects of intermittent or continuous energy restriction on weight loss and metabolic disease risk markers: a randomized trial in young overweight women. <i>International Journal of Obesity</i> , 2011 , 35, 714-27	5.5	413

546	Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. <i>American Journal of Human Genetics</i> , 2019 , 104, 21-34	11	363
545	Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. <i>Journal of Clinical Oncology</i> , 2004 , 22, 1605-13	2.2	343
544	Oxidative stress in cancer associated fibroblasts drives tumor-stroma co-evolution: A new paradigm for understanding tumor metabolism, the field effect and genomic instability in cancer cells. <i>Cell Cycle</i> , 2010 , 9, 3256-76	4.7	341
543	Association of gain and loss of weight before and after menopause with risk of postmenopausal breast cancer in the Iowa women's health study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005 , 14, 656-61	4	338
542	Autophagy in cancer associated fibroblasts promotes tumor cell survival: Role of hypoxia, HIF1 induction and NFB activation in the tumor stromal microenvironment. <i>Cell Cycle</i> , 2010 , 9, 3515-33	4.7	321
541	ICI 182,780 (Faslodex): development of a novel, "pure" antiestrogen. <i>Cancer</i> , 2000 , 89, 817-25	6.4	320
540	Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group. <i>Journal of Clinical Oncology</i> , 1996 , 14, 2000-11	2.2	320
539	Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. <i>Journal of Clinical Oncology</i> , 2008 , 26, 1051-7	2.2	312
538	Evidence for a stromal-epithelial "lactate shuttle" in human tumors: MCT4 is a marker of oxidative stress in cancer-associated fibroblasts. <i>Cell Cycle</i> , 2011 , 10, 1772-83	4.7	310
537	Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: a nested case-control study. <i>Journal of the National Cancer Institute</i> , 2011 , 103, 744-52	9.7	306
536	Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. <i>Lancet Oncology, The</i> , 2006 , 7, 633-43	21.7	295
535	Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma. <i>Cancer</i> , 1998 , 83, 1142-1152	6.4	292
534	A putative human breast stem cell population is enriched for steroid receptor-positive cells. <i>Developmental Biology</i> , 2005 , 277, 443-56	3.1	289
533	A comparison of the metastatic pattern of infiltrating lobular carcinoma and infiltrating duct carcinoma of the breast. <i>British Journal of Cancer</i> , 1984 , 50, 23-30	8.7	277
532	Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. <i>Cancer</i> , 2003 , 98, 229-38	6.4	271
531	Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. <i>Lancet Oncology, The</i> , 2015 , 16, 67-75	21.7	270
530	Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer. <i>Lancet, The</i> , 1995 , 345, 29-30	40	268
529	The kinetics of human granulopoiesis following treatment with granulocyte colony-stimulating factor in vivo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1989 , 86, 9499-503	11.5	267

528	The effect of age and menstrual cycle upon proliferative activity of the normal human breast. <i>British Journal of Cancer</i> , 1988 , 58, 163-70	8.7	261
527	Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. <i>Breast Cancer Research</i> , 2013 , 15, R92	8.3	248
526	Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial. <i>Journal of Clinical Oncology</i> , 2004 , 22, 4261-71	2.2	243
525	Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT-B. <i>Breast Cancer Research and Treatment</i> , 1999 , 55, 189-94	4.4	242
524	The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer. <i>British Journal of Cancer</i> , 1989 , 60, 121-5	8.7	239
523	The effect of intermittent energy and carbohydrate restriction v. daily energy restriction on weight loss and metabolic disease risk markers in overweight women. <i>British Journal of Nutrition</i> , 2013 , 110, 1534-47	3.6	229
522	Ketones and lactate increase cancer cell "stemness," driving recurrence, metastasis and poor clinical outcome in breast cancer: achieving personalized medicine via Metabolo-Genomics. <i>Cell Cycle</i> , 2011 , 10, 1271-86	4.7	229
521	Estrogen sensitivity of normal human breast tissue in vivo and implanted into athymic nude mice: analysis of the relationship between estrogen-induced proliferation and progesterone receptor expression. <i>Breast Cancer Research and Treatment</i> , 1997 , 45, 121-33	4.4	225
520	Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial. <i>Journal of Clinical Oncology</i> , 2010 , 28, 3411-5	2.2	224
519	Warburg meets autophagy: cancer-associated fibroblasts accelerate tumor growth and metastasis via oxidative stress, mitophagy, and aerobic glycolysis. <i>Antioxidants and Redox Signaling</i> , 2012 , 16, 1264-84	8.4	222
518	A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. <i>European Journal of Cancer</i> , 1996 , 32A, 404-12	7.5	222
517	Screening for psychiatric morbidity in patients with advanced breast cancer: validation of two self-report questionnaires. <i>British Journal of Cancer</i> , 1991 , 64, 353-6	8.7	218
516	Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme. <i>Journal of Medical Genetics</i> , 2003 , 40, 807-14	5.8	217
515	Caveolin-1 and cancer metabolism in the tumor microenvironment: markers, models, and mechanisms. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2012 , 7, 423-67	34	216
514	Hyperactivation of oxidative mitochondrial metabolism in epithelial cancer cells in situ: visualizing the therapeutic effects of metformin in tumor tissue. <i>Cell Cycle</i> , 2011 , 10, 4047-64	4.7	216
513	The autophagic tumor stroma model of cancer: Role of oxidative stress and ketone production in fueling tumor cell metabolism. <i>Cell Cycle</i> , 2010 , 9, 3485-505	4.7	215
512	Tumor cells induce the cancer associated fibroblast phenotype via caveolin-1 degradation: implications for breast cancer and DCIS therapy with autophagy inhibitors. <i>Cell Cycle</i> , 2010 , 9, 2423-33	4.7	208
511	The Angelina Jolie effect: how high celebrity profile can have a major impact on provision of cancer related services. <i>Breast Cancer Research</i> , 2014 , 16, 442	8.3	207

510	Tamoxifen for the prevention of breast cancer: psychosocial impact on women participating in two randomized controlled trials. <i>Journal of Clinical Oncology</i> , 2001 , 19, 1885-92	2.2	203
509	Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. <i>Cancer Research</i> , 1994 , 54, 408-14	10.1	200
508	Metabolic reprogramming of cancer-associated fibroblasts by TGF- β drives tumor growth: connecting TGF- β signaling with "Warburg-like" cancer metabolism and L-lactate production. <i>Cell Cycle</i> , 2012 , 11, 3019-35	4.7	194
507	High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. <i>Breast Cancer Research and Treatment</i> , 2001 , 67, 111-6	4.4	194
506	Cancer cells metabolically "fertilize" the tumor microenvironment with hydrogen peroxide, driving the Warburg effect: implications for PET imaging of human tumors. <i>Cell Cycle</i> , 2011 , 10, 2504-20	4.7	193
505	Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma 1998 , 83, 1142		193
504	Quality of life of postmenopausal women in the ATAC ("Arimidex", tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2006 , 100, 273-84	4.4	191
503	Stromal-epithelial metabolic coupling in cancer: integrating autophagy and metabolism in the tumor microenvironment. <i>International Journal of Biochemistry and Cell Biology</i> , 2011 , 43, 1045-51	5.6	189
502	A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO. <i>Journal of Medical Genetics</i> , 2004 , 41, 474-80	5.8	189
501	Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group. <i>Cancer Treatment Reviews</i> , 2008 , 34 Suppl 1, S3-18	14.4	187
500	Risk determination and prevention of breast cancer. <i>Breast Cancer Research</i> , 2014 , 16, 446	8.3	180
499	Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study. <i>Psycho-Oncology</i> , 2004 , 13, 61-6	3.9	180
498	Autophagy and senescence in cancer-associated fibroblasts metabolically supports tumor growth and metastasis via glycolysis and ketone production. <i>Cell Cycle</i> , 2012 , 11, 2285-302	4.7	179
497	Preventive therapy for breast cancer: a consensus statement. <i>Lancet Oncology, The</i> , 2011 , 12, 496-503	21.7	177
496	Tamoxifen ("Nolvadex"): a review. <i>Cancer Treatment Reviews</i> , 2002 , 28, 165-80	14.4	171
495	HIF1- α functions as a tumor promoter in cancer associated fibroblasts, and as a tumor suppressor in breast cancer cells: Autophagy drives compartment-specific oncogenesis. <i>Cell Cycle</i> , 2010 , 9, 3534-51	4.7	168
494	Effects of soy-protein supplementation on epithelial proliferation in the histologically normal human breast. <i>American Journal of Clinical Nutrition</i> , 1998 , 68, 1431S-1435S	7	166
493	Two-week dietary soy supplementation has an estrogenic effect on normal premenopausal breast. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999 , 84, 4017-24	5.6	166

492	Hydrogen peroxide fuels aging, inflammation, cancer metabolism and metastasis: the seed and soil also needs "fertilizer". <i>Cell Cycle</i> , 2011 , 10, 2440-9	4.7	165
491	Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a Clinical Cancer Genetics service setting: risks of breast/ovarian cancer quoted should reflect the cancer burden in the family. <i>BMC Cancer</i> , 2008 , 8, 155	4.8	165
490	Understanding the "lethal" drivers of tumor-stroma co-evolution: emerging role(s) for hypoxia, oxidative stress and autophagy/mitophagy in the tumor micro-environment. <i>Cancer Biology and Therapy</i> , 2010 , 10, 537-42	4.6	155
489	The impact of genetic counselling on risk perception in women with a family history of breast cancer. <i>British Journal of Cancer</i> , 1994 , 70, 934-8	8.7	155
488	Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer. <i>British Journal of Cancer</i> , 1996 , 74, 300-8	8.7	153
487	Psychiatric morbidity in patients with advanced cancer of the breast: prevalence measured by two self-rating questionnaires. <i>British Journal of Cancer</i> , 1991 , 64, 349-52	8.7	152
486	The proliferation of normal human breast tissue implanted into athymic nude mice is stimulated by estrogen but not progesterone. <i>Endocrinology</i> , 1995 , 136, 164-71	4.8	150
485	Steroid-hormone receptors and survival after first relapse in breast cancer. <i>Lancet, The</i> , 1984 , 1, 588-91	4.0	149
484	CDK inhibitors (p16/p19/p21) induce senescence and autophagy in cancer-associated fibroblasts, "fueling" tumor growth via paracrine interactions, without an increase in neo-angiogenesis. <i>Cell Cycle</i> , 2012 , 11, 3599-610	4.7	147
483	Perception of risk in women with a family history of breast cancer. <i>British Journal of Cancer</i> , 1993 , 67, 612-4	8.7	147
482	Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women. <i>New England Journal of Medicine</i> , 2021 , 384, 428-439	59.2	143
481	Critical assessment of new risk factors for breast cancer: considerations for development of an improved risk prediction model. <i>Endocrine-Related Cancer</i> , 2007 , 14, 169-87	5.7	141
480	Mitochondrial metabolism in cancer metastasis: visualizing tumor cell mitochondria and the "reverse Warburg effect" in positive lymph node tissue. <i>Cell Cycle</i> , 2012 , 11, 1445-54	4.7	139
479	Assessment of tumour vascularity as a prognostic factor in lymph node negative invasive breast cancer. <i>European Journal of Cancer</i> , 1993 , 29A, 1141-5	7.5	137
478	Understanding the Warburg effect and the prognostic value of stromal caveolin-1 as a marker of a lethal tumor microenvironment. <i>Breast Cancer Research</i> , 2011 , 13, 213	8.3	136
477	Anti-estrogen resistance in breast cancer is induced by the tumor microenvironment and can be overcome by inhibiting mitochondrial function in epithelial cancer cells. <i>Cancer Biology and Therapy</i> , 2011 , 12, 924-38	4.6	134
476	The autophagic tumor stroma model of cancer or "battery-operated tumor growth": A simple solution to the autophagy paradox. <i>Cell Cycle</i> , 2010 , 9, 4297-306	4.7	134
475	A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer. <i>Journal of Clinical Oncology</i> , 1986 , 4, 1326-30	2.2	134

474	Estrogen responsiveness and control of normal human breast proliferation. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 1998 , 3, 23-35	2.4	133
473	CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations. <i>Clinical Pharmacology and Therapeutics</i> , 2014 , 95, 216-27	6.1	131
472	Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials. <i>Cancer</i> , 2005 , 104, 236-9	6.4	130
471	Energy transfer in "parasitic" cancer metabolism: mitochondria are the powerhouse and Achilles' heel of tumor cells. <i>Cell Cycle</i> , 2011 , 10, 4208-16	4.7	129
470	Response after withdrawal of tamoxifen and progestogens in advanced breast cancer. <i>Annals of Oncology</i> , 1992 , 3, 611-7	10.3	128
469	Origins of breast cancer subtypes and therapeutic implications. <i>Nature Clinical Practice Oncology</i> , 2007 , 4, 516-25		126
468	Mammographic density adds accuracy to both the Tyrer-Cuzick and Gail breast cancer risk models in a prospective UK screening cohort. <i>Breast Cancer Research</i> , 2015 , 17, 147	8.3	124
467	Contralateral mastectomy improves survival in women with BRCA1/2-associated breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013 , 140, 135-42	4.4	119
466	Mitochondria "fuel" breast cancer metabolism: fifteen markers of mitochondrial biogenesis label epithelial cancer cells, but are excluded from adjacent stromal cells. <i>Cell Cycle</i> , 2012 , 11, 4390-401	4.7	118
465	Glutamine fuels a vicious cycle of autophagy in the tumor stroma and oxidative mitochondrial metabolism in epithelial cancer cells: implications for preventing chemotherapy resistance. <i>Cancer Biology and Therapy</i> , 2011 , 12, 1085-97	4.6	118
464	Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the 'Arimidex and tamoxifen alone or in combination' (ATAC) trial. <i>British Journal of Cancer</i> , 2001 , 85, 317-24	8.7	116
463	Transcriptional evidence for the "Reverse Warburg Effect" in human breast cancer tumor stroma and metastasis: similarities with oxidative stress, inflammation, Alzheimer's disease, and "Neuron-Glia Metabolic Coupling". <i>Aging</i> , 2010 , 2, 185-99	5.6	116
462	Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial. <i>Lancet, The</i> , 2016 , 387, 866-73	4.0	114
461	Ketone body utilization drives tumor growth and metastasis. <i>Cell Cycle</i> , 2012 , 11, 3964-71	4.7	113
460	Glycolytic cancer associated fibroblasts promote breast cancer tumor growth, without a measurable increase in angiogenesis: evidence for stromal-epithelial metabolic coupling. <i>Cell Cycle</i> , 2010 , 9, 2412-22	4.7	112
459	Insulin-like growth factor (IGF)-I, IGF binding protein-3, and breast cancer risk: eight years on. <i>Endocrine-Related Cancer</i> , 2006 , 13, 273-8	5.7	111
458	BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives. <i>European Journal of Cancer</i> , 2006 , 42, 1143-50	7.5	110
457	Uptake of risk-reducing surgery in unaffected women at high risk of breast and ovarian cancer is risk, age, and time dependent. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009 , 18, 2318-24	4	109

456	Reduction in apoptosis relative to mitosis in histologically normal epithelium accompanies fibrocystic change and carcinoma of the premenopausal human breast. <i>Journal of Pathology</i> , 1992 , 167, 25-32	9.4	108
455	Oral contraceptive (OCP) use increases proliferation and decreases oestrogen receptor content of epithelial cells in the normal human breast. <i>International Journal of Cancer</i> , 1991 , 48, 206-10	7.5	107
454	MRI breast screening in high-risk women: cancer detection and survival analysis. <i>Breast Cancer Research and Treatment</i> , 2014 , 145, 663-72	4.4	105
453	Cytokine production and inflammation drive autophagy in the tumor microenvironment: role of stromal caveolin-1 as a key regulator. <i>Cell Cycle</i> , 2011 , 10, 1784-93	4.7	103
452	Clinical follow-up after bilateral risk reducing ("prophylactic") mastectomy: mental health and body image outcomes. <i>Psycho-Oncology</i> , 2000 , 9, 462-72	3.9	103
451	Effects of anastrozole on cognitive performance in postmenopausal women: a randomised, double-blind chemoprevention trial (IBIS II). <i>Lancet Oncology, The</i> , 2008 , 9, 953-61	21.7	101
450	The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2004 , 18, 47-66	6.5	101
449	Caveolin-1 and mitochondrial SOD2 (MnSOD) function as tumor suppressors in the stromal microenvironment: a new genetically tractable model for human cancer associated fibroblasts. <i>Cancer Biology and Therapy</i> , 2011 , 11, 383-94	4.6	100
448	The prognostic significance of two epithelial membrane antigens expressed by human mammary carcinomas. <i>International Journal of Cancer</i> , 1984 , 33, 299-304	7.5	99
447	Serum soluble vascular cell adhesion molecule-1: role as a surrogate marker of angiogenesis. <i>Journal of the National Cancer Institute</i> , 2000 , 92, 1329-36	9.7	98
446	Mitochondrial oxidative stress in cancer-associated fibroblasts drives lactate production, promoting breast cancer tumor growth: understanding the aging and cancer connection. <i>Cell Cycle</i> , 2011 , 10, 4065-73	4.7	96
445	CTGF drives autophagy, glycolysis and senescence in cancer-associated fibroblasts via HIF1 activation, metabolically promoting tumor growth. <i>Cell Cycle</i> , 2012 , 11, 2272-84	4.7	96
444	Energy balance in early breast cancer patients receiving adjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2004 , 83, 201-10	4.4	96
443	Two-compartment tumor metabolism: autophagy in the tumor microenvironment and oxidative mitochondrial metabolism (OXPHOS) in cancer cells. <i>Cell Cycle</i> , 2012 , 11, 2545-56	4.7	95
442	The removal of multiplicative, systematic bias allows integration of breast cancer gene expression datasets - improving meta-analysis and prediction of prognosis. <i>BMC Medical Genomics</i> , 2008 , 1, 42	3.7	95
441	Firm R&D, innovation and easing financial constraints in China: Does corporate tax reform matter?. <i>Research Policy</i> , 2016 , 45, 1996-2007	7.5	94
440	Regulation of human breast epithelial stem cells. <i>Cell Proliferation</i> , 2003 , 36 Suppl 1, 45-58	7.9	93
439	Carcinomatous meningitis in patients with breast cancer. An aggressive disease variant. <i>Cancer</i> , 1994 , 74, 3135-41	6.4	93

438	Effect of tamoxifen on Ki67 labelling index in human breast tumours and its relationship to oestrogen and progesterone receptor status. <i>British Journal of Cancer</i> , 1993 , 67, 606-11	8.7	92
437	Survival in prospectively ascertained familial breast cancer: analysis of a series stratified by tumour characteristics, BRCA mutations and oophorectomy. <i>International Journal of Cancer</i> , 2002 , 101, 555-9	7.5	91
436	Risk perception and cancer worry: an exploratory study of the impact of genetic risk counselling in women with a family history of breast cancer. <i>Journal of Medical Genetics</i> , 2001 , 38, 139	5.8	91
435	Non-standard management of breast cancer increases with age in the UK: a population based cohort of women > or =65 years. <i>British Journal of Cancer</i> , 2007 , 96, 1197-203	8.7	90
434	Breast cancer risk-assessment models. <i>Breast Cancer Research</i> , 2007 , 9, 213	8.3	90
433	Mitochondrial fission induces glycolytic reprogramming in cancer-associated myofibroblasts, driving stromal lactate production, and early tumor growth. <i>Oncotarget</i> , 2012 , 3, 798-810	3.3	90
432	Ketone bodies and two-compartment tumor metabolism: stromal ketone production fuels mitochondrial biogenesis in epithelial cancer cells. <i>Cell Cycle</i> , 2012 , 11, 3956-63	4.7	89
431	Psychological support needs for women at high genetic risk of breast cancer: some preliminary indicators. <i>Psycho-Oncology</i> , 1998 , 7, 402-12	3.9	89
430	Mitochondrial biogenesis in epithelial cancer cells promotes breast cancer tumor growth and confers autophagy resistance. <i>Cell Cycle</i> , 2012 , 11, 4174-80	4.7	88
429	Pure oestrogen antagonists for the treatment of advanced breast cancer. <i>Endocrine-Related Cancer</i> , 2006 , 13, 689-706	5.7	87
428	The definition of the 'no change' category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast. <i>European Journal of Cancer & Clinical Oncology</i> , 1988 , 24, 1567-72		84
427	Understanding the metabolic basis of drug resistance: therapeutic induction of the Warburg effect kills cancer cells. <i>Cell Cycle</i> , 2011 , 10, 2521-8	4.7	83
426	Induction of apoptosis by tamoxifen and ICI 182780 in primary breast cancer. <i>International Journal of Cancer</i> , 1997 , 72, 608-13	7.5	82
425	A randomised study to compare the effect of the luteinising hormone releasing hormone (LHRH) analogue goserelin with or without tamoxifen in pre- and perimenopausal patients with advanced breast cancer. <i>European Journal of Cancer</i> , 1995 , 31A, 137-42	7.5	82
424	Advances in aromatase inhibition: clinical efficacy and tolerability in the treatment of breast cancer. <i>Clinical Cancer Research</i> , 2001 , 7, 2620-35	12.9	82
423	Pyruvate kinase expression (PKM1 and PKM2) in cancer-associated fibroblasts drives stromal nutrient production and tumor growth. <i>Cancer Biology and Therapy</i> , 2011 , 12, 1101-13	4.6	80
422	Type I insulin-like growth factor receptor gene expression in normal human breast tissue treated with oestrogen and progesterone. <i>British Journal of Cancer</i> , 1997 , 75, 251-7	8.7	80
421	Assessing individual breast cancer risk within the U.K. National Health Service Breast Screening Program: a new paradigm for cancer prevention. <i>Cancer Prevention Research</i> , 2012 , 5, 943-51	3.2	79

420	The effect of intermittent versus chronic energy restriction on breast cancer risk biomarkers in premenopausal women: a randomised pilot trial. <i>Breast Cancer Research</i> , 2008 , 10,	8.3	78
419	Adherence to hormone therapy in a chemoprevention randomised trial. <i>Breast Cancer Research</i> , 2008 , 10,	8.3	78
418	Effects of oestrogen on gene expression in the epithelium and stroma of the normal human breast. <i>Breast Cancer Research</i> , 2005 , 7, 1	8.3	78
417	The future of breast cancer prevention. <i>Breast Cancer Research</i> , 2005 , 7, 1	8.3	78
416	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. <i>Nature Genetics</i> , 2020 , 52, 572-581	36.3	76
415	Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy. <i>Breast Cancer Research and Treatment</i> , 2011 , 125, 279-87	4.4	76
414	Surveillance for familial breast cancer: Differences in outcome according to BRCA mutation status. <i>International Journal of Cancer</i> , 2007 , 121, 1017-20	7.5	76
413	Mechanism of action of adjuvant chemotherapy in early breast cancer. <i>Lancet, The</i> , 1986 , 2, 411-4	4.0	76
412	Changes in the extracellular matrix of the normal human breast during the menstrual cycle. <i>Cell and Tissue Research</i> , 1992 , 268, 167-77	4.2	75
411	Screening by mammography, women with a family history of breast cancer. <i>European Journal of Cancer</i> , 1998 , 34, 937-40	7.5	74
410	Risk reducing mastectomy: outcomes in 10 European centres. <i>Journal of Medical Genetics</i> , 2009 , 46, 254-8.8	8.8	73
409	The objective measurement of remission and progression in metastatic breast cancer by use of serum tumour markers. European Group for Serum Tumour Markers in Breast Cancer. <i>European Journal of Cancer</i> , 1999 , 35, 47-53	7.5	73
408	Use of Single-Nucleotide Polymorphisms and Mammographic Density Plus Classic Risk Factors for Breast Cancer Risk Prediction. <i>JAMA Oncology</i> , 2018 , 4, 476-482	13.4	72
407	Sclerosis of lytic bone metastases after disodium aminohydroxypropylidene bisphosphonate (APD) in patients with breast carcinoma. <i>BMJ: British Medical Journal</i> , 1988 , 297, 772-3		72
406	Potential Benefits and Harms of Intermittent Energy Restriction and Intermittent Fasting Amongst Obese, Overweight and Normal Weight Subjects-A Narrative Review of Human and Animal Evidence. <i>Behavioral Sciences (Basel, Switzerland)</i> , 2017 , 7,	2.3	71
405	Lung cancer after treatment for Hodgkin's lymphoma: a systematic review. <i>Lancet Oncology, The</i> , 2005 , 6, 773-9	21.7	71
404	Carcinomatous meningitis in solid tumours. <i>Annals of Oncology</i> , 1996 , 7, 773-86	10.3	70
403	Migration and Inequality in Xinjiang: A Survey of Han and Uyghur Migrants in Urumqi. <i>Eurasian Geography and Economics</i> , 2011 , 52, 119-139	3.2	69

402	Haemopoietic cells mobilised into the circulation by lenograstim as alternative to bone marrow for allogeneic transplants. <i>Lancet, The</i> , 1993 , 341, 369	4.0	69
401	Picking 'Winners' in China: Do subsidies matter for indigenous innovation and firm productivity?. <i>China Economic Review</i> , 2017 , 44, 154-165	3.9	68
400	Serum 1,25-dihydroxyvitamin D may be related inversely to disease activity in breast cancer patients with bone metastases. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997 , 82, 118-22	5.6	68
399	Faslodex (ICI 182780). an oestrogen receptor downregulator. <i>European Journal of Cancer</i> , 2000 , 36 Suppl 4, S87-8	7.5	68
398	Uptake of tamoxifen in consecutive premenopausal women under surveillance in a high-risk breast cancer clinic. <i>British Journal of Cancer</i> , 2014 , 110, 1681-7	8.7	67
397	Endometrial cancer and venous thromboembolism in women under age 50 who take tamoxifen for prevention of breast cancer: a systematic review. <i>Cancer Treatment Reviews</i> , 2012 , 38, 318-28	14.4	67
396	Metabolic reprogramming and two-compartment tumor metabolism: opposing role(s) of HIF1 α and HIF2 α in tumor-associated fibroblasts and human breast cancer cells. <i>Cell Cycle</i> , 2012 , 11, 3280-9	4.7	67
395	Effects of 4-hydroxytamoxifen and a novel pure antioestrogen (ICI 182780) on the clonogenic growth of human breast cancer cells in vitro. <i>British Journal of Cancer</i> , 1994 , 70, 204-11	8.7	67
394	Long-term effects of anastrozole on bone mineral density: 7-year results from the ATAC trial. <i>Annals of Oncology</i> , 2011 , 22, 857-862	10.3	66
393	Evaluation of the current knowledge limitations in breast cancer research: a gap analysis. <i>Breast Cancer Research</i> , 2008 , 10, R26	8.3	66
392	Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group. <i>Cancer</i> , 1998 , 83, 1142-52	6.4	66
391	Effects of cyclin D1 gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study. <i>Breast Cancer Research</i> , 2012 , 14, R57	8.3	65
390	Oncogenes and inflammation rewire host energy metabolism in the tumor microenvironment: RAS and NF κ B target stromal MCT4. <i>Cell Cycle</i> , 2013 , 12, 2580-97	4.7	65
389	Addition of pathology and biomarker information significantly improves the performance of the Manchester scoring system for BRCA1 and BRCA2 testing. <i>Journal of Medical Genetics</i> , 2009 , 46, 811-7	5.8	65
388	Steroid receptors in human breast cancer. <i>Trends in Endocrinology and Metabolism</i> , 2004 , 15, 316-23	8.8	65
387	Longer term effects of the Angelina Jolie effect: increased risk-reducing mastectomy rates in BRCA carriers and other high-risk women. <i>Breast Cancer Research</i> , 2015 , 17, 143	8.3	64
386	Mitochondrial dysfunction in breast cancer cells prevents tumor growth: understanding chemoprevention with metformin. <i>Cell Cycle</i> , 2013 , 12, 172-82	4.7	64
385	BRCA1 mutations drive oxidative stress and glycolysis in the tumor microenvironment: implications for breast cancer prevention with antioxidant therapies. <i>Cell Cycle</i> , 2012 , 11, 4402-13	4.7	64

384	C-erbB2 mRNA expression in human breast tumours: comparison with c-erbB2 DNA amplification and correlation with prognosis. <i>British Journal of Cancer</i> , 1990 , 61, 39-45	8.7	64
383	New endocrine therapies for breast cancer. <i>European Journal of Cancer</i> , 1996 , 32A, 576-88	7.5	63
382	DNA analysis by flow cytometry, response to endocrine treatment and prognosis in advanced carcinoma of the breast. <i>British Journal of Cancer</i> , 1987 , 55, 553-9	8.7	63
381	Oestrogen and breast cancer: results from the WHI trial. <i>Lancet Oncology, The</i> , 2012 , 13, 437-8	21.7	62
380	Effects of oestrogen on gene expression in epithelium and stroma of normal human breast tissue. <i>Endocrine-Related Cancer</i> , 2006 , 13, 617-28	5.7	62
379	Familial breast cancer. <i>BMJ: British Medical Journal</i> , 1994 , 308, 183-7		61
378	Prevalence of BRCA1 and BRCA2 mutations in triple negative breast cancer. <i>Journal of Medical Genetics</i> , 2011 , 48, 520-2	5.8	59
377	Late toxicity is not increased in BRCA1/BRCA2 mutation carriers undergoing breast radiotherapy in the United Kingdom. <i>Clinical Cancer Research</i> , 2006 , 12, 7025-32	12.9	59
376	Doxorubicin in advanced breast cancer: influence of schedule on response, survival and quality of life. <i>European Journal of Cancer</i> , 1992 , 28A, 1023-8	7.5	57
375	Tenascin distribution in the normal human breast is altered during the menstrual cycle and in carcinoma. <i>Differentiation</i> , 1990 , 42, 199-207	3.5	57
374	Accelerated aging in the tumor microenvironment: connecting aging, inflammation and cancer metabolism with personalized medicine. <i>Cell Cycle</i> , 2011 , 10, 2059-63	4.7	56
373	Occurrence of a fetal fibroblast phenotype in familial breast cancer. <i>International Journal of Cancer</i> , 1986 , 37, 831-6	7.5	56
372	Controlled trial of adjuvant chemotherapy with cyclophosphamide, methotrexate, and fluorouracil for breast cancer. <i>Lancet, The</i> , 1984 , 2, 307-11	4.0	56
371	Histological detection of oestrogen receptor in human breast carcinomas. <i>Lancet, The</i> , 1980 , 1, 171-3	4.0	56
370	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. <i>Nature Genetics</i> , 2020 , 52, 56-73	36.3	56
369	Matrix remodeling stimulates stromal autophagy, "fueling" cancer cell mitochondrial metabolism and metastasis. <i>Cell Cycle</i> , 2011 , 10, 2021-34	4.7	55
368	Is cancer a metabolic rebellion against host aging? In the quest for immortality, tumor cells try to save themselves by boosting mitochondrial metabolism. <i>Cell Cycle</i> , 2012 , 11, 253-63	4.7	55
367	Mammographic breast density refines Tyrer-Cuzick estimates of breast cancer risk in high-risk women: findings from the placebo arm of the International Breast Cancer Intervention Study I. <i>Breast Cancer Research</i> , 2014 , 16, 451	8.3	54

366	Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial. <i>Lancet, The</i> , 2020 , 395, 117-122	4.0	54
365	Influence of comorbidities and age on risk of death without recurrence: a retrospective analysis of the Arimidex, Tamoxifen Alone or in Combination trial. <i>Journal of Clinical Oncology</i> , 2011 , 29, 4266-72	2.2	53
364	Objective measurement of therapeutic response in breast cancer using tumour markers. <i>British Journal of Cancer</i> , 1991 , 64, 757-63	8.7	53
363	Epidermal and transforming growth factor alpha in patients with breast tumours. <i>British Journal of Cancer</i> , 1989 , 59, 605-9	8.7	53
362	Can diet and lifestyle prevent breast cancer: what is the evidence?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015 , e66-73	7.1	52
361	Treatment of advanced prostatic cancer with LHRH analogue ICI 118630: clinical response and hormonal mechanisms. <i>Lancet, The</i> , 1983 , 2, 415-9	4.0	52
360	Endocrine therapy for advanced carcinoma of the breast: relationship between the effect of tamoxifen upon concentrations of progesterone receptor and subsequent response to treatment. <i>Cancer Research</i> , 1987 , 47, 300-4	10.1	52
359	Impact of a Panel of 88 Single Nucleotide Polymorphisms on the Risk of Breast Cancer in High-Risk Women: Results From Two Randomized Tamoxifen Prevention Trials. <i>Journal of Clinical Oncology</i> , 2017 , 35, 743-750	2.2	51
358	Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial. <i>Lancet Oncology, The</i> , 2014 , 15, 1460-1468	21.7	51
357	Should aromatase inhibitors be used as initial adjuvant treatment or sequenced after tamoxifen?. <i>British Journal of Cancer</i> , 2006 , 94, 460-4	8.7	51
356	Controlled trial of adjuvant chemotherapy with melphalan for breast cancer. <i>Lancet, The</i> , 1983 , 1, 839-43	4.0	51
355	Review of recent trials of chemotherapy for advanced breast cancer: the taxanes. <i>European Journal of Cancer</i> , 1997 , 33, 2183-93	7.5	50
354	Older women with operable breast cancer are less likely to have surgery. <i>British Journal of Surgery</i> , 2007 , 94, 1209-15	5.3	50
353	Fibroblasts from relatives of patients with hereditary breast cancer show fetal-like behaviour in vitro. <i>Lancet, The</i> , 1987 , 1, 1455-7	4.0	50
352	Allelic imbalance on chromosome 1 in human breast cancer. II. Microsatellite repeat analysis. <i>Genes Chromosomes and Cancer</i> , 1995 , 12, 24-31	5	49
351	Preliminary report on use of depot formulation of LHRH analogue ICI 118630 (Zoladex) in patients with prostatic cancer. <i>British Medical Journal</i> , 1985 , 290, 185-7		49
350	Uptake of screening and prevention in women at very high risk of breast cancer. <i>Lancet, The</i> , 2001 , 358, 889-90	4.0	48
349	Single dose versus daily intravenous aminohydroxypropylidene biphosphonate (APD) for the hypercalcaemia of malignancy. <i>British Medical Journal</i> , 1988 , 296, 811-4		48

348	Improvement in risk prediction, early detection and prevention of breast cancer in the NHS Breast Screening Programme and family history clinics: a dual cohort study. <i>Programme Grants for Applied Research</i> , 2016 , 4, 1-210	1.5	48
347	Breast cancer risk feedback to women in the UK NHS breast screening population. <i>British Journal of Cancer</i> , 2016 , 114, 1045-52	8.7	48
346	Menopausal symptoms and bone health in women undertaking risk reducing bilateral salpingo-oophorectomy: significant bone health issues in those not taking HRT. <i>British Journal of Cancer</i> , 2011 , 105, 22-7	8.7	46
345	The clearance and bioavailability of pamidronate in patients with breast cancer and bone metastases. <i>Calcified Tissue International</i> , 1991 , 49, 433-5	3.9	46
344	Targeting tumor-initiating cells: eliminating anabolic cancer stem cells with inhibitors of protein synthesis or by mimicking caloric restriction. <i>Oncotarget</i> , 2015 , 6, 4585-601	3.3	46
343	Impacts of Migration and Remittances on Ethnic Income Inequality in Rural China. <i>World Development</i> , 2017 , 94, 200-211	5.5	45
342	Risk-reducing surgery increases survival in BRCA1/2 mutation carriers unaffected at time of family referral. <i>Breast Cancer Research and Treatment</i> , 2013 , 142, 611-8	4.4	45
341	Response to intravenous bisphosphonate therapy in hypercalcaemic patients with and without bone metastases: the role of parathyroid hormone-related protein. <i>British Journal of Cancer</i> , 1994 , 70, 169-72	8.7	43
340	The impact of a panel of 18 SNPs on breast cancer risk in women attending a UK familial screening clinic: a case-control study. <i>Journal of Medical Genetics</i> , 2017 , 54, 111-113	5.8	42
339	Indigenous innovation with heterogeneous risk and new firm survival in a transitioning Chinese economy. <i>Research Policy</i> , 2015 , 44, 1866-1876	7.5	42
338	JNK1 stress signaling is hyper-activated in high breast density and the tumor stroma: connecting fibrosis, inflammation, and stemness for cancer prevention. <i>Cell Cycle</i> , 2014 , 13, 580-99	4.7	42
337	Cigarette smoke metabolically promotes cancer, via autophagy and premature aging in the host stromal microenvironment. <i>Cell Cycle</i> , 2013 , 12, 818-25	4.7	42
336	Endocrinology and hormone therapy in breast cancer: aromatase inhibitors versus antioestrogens. <i>Breast Cancer Research</i> , 2004 , 6, 269-74	8.3	42
335	Phenotypic heterogeneity in breast fibroblasts: functional anomaly in fibroblasts from histologically normal tissue adjacent to carcinoma. <i>International Journal of Cancer</i> , 1994 , 59, 25-32	7.5	42
334	Hereditary ovarian cancer and two-compartment tumor metabolism: epithelial loss of BRCA1 induces hydrogen peroxide production, driving oxidative stress and NF κ B activation in the tumor stroma. <i>Cell Cycle</i> , 2012 , 11, 4152-66	4.7	41
333	Energy balance adiposity and breast cancer - energy restriction strategies for breast cancer prevention. <i>Obesity Reviews</i> , 2006 , 7, 33-47	10.6	41
332	O6-(4-bromophenyl)guanine reverses temozolomide resistance in human breast tumour MCF-7 cells and xenografts. <i>British Journal of Cancer</i> , 2005 , 93, 1152-6	8.7	41
331	Long-term outcomes of breast cancer in women aged 30 years or younger, based on family history, pathology and BRCA1/BRCA2/TP53 status. <i>British Journal of Cancer</i> , 2010 , 102, 1091-8	8.7	40

330	Tumour angiogenesis as a prognostic marker in infiltrating lobular carcinoma of the breast. <i>Journal of Pathology</i> , 1996 , 180, 44-9	9.4	40
329	Ethanol exposure induces the cancer-associated fibroblast phenotype and lethal tumor metabolism: implications for breast cancer prevention. <i>Cell Cycle</i> , 2013 , 12, 289-301	4.7	39
328	Assessment of hormone dependence of comedo ductal carcinoma in situ of the breast. <i>Journal of the National Cancer Institute</i> , 1997 , 89, 1059-65	9.7	39
327	Fulvestrant ('Faslodex'): current and future role in breast cancer management. <i>Critical Reviews in Oncology/Hematology</i> , 2006 , 57, 265-73	7	39
326	Vascular effects of aromatase inhibitors: data from clinical trials. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2005 , 95, 143-9	5.1	38
325	Screening younger women with a family history of breast cancer--does early detection improve outcome?. <i>European Journal of Cancer</i> , 2006 , 42, 1385-90	7.5	38
324	Agglomeration, (un)-related variety and new firm survival in China: Do local subsidies matter?. <i>Papers in Regional Science</i> , 2018 , 97, 485-500	1.8	37
323	Metabolic remodeling of the tumor microenvironment: migration stimulating factor (MSF) reprograms myofibroblasts toward lactate production, fueling anabolic tumor growth. <i>Cell Cycle</i> , 2012 , 11, 3403-14	4.7	37
322	Surgical decisions made by 158 women with hereditary breast cancer aged . <i>European Journal of Surgical Oncology</i> , 2005 , 31, 1112-8	3.6	37
321	Energy balance in patients with advanced NSCLC, metastatic melanoma and metastatic breast cancer receiving chemotherapy--a longitudinal study. <i>British Journal of Cancer</i> , 2005 , 92, 673-80	8.7	37
320	Effects of short-term antiestrogen treatment of primary breast cancer on estrogen receptor mRNA and protein expression and on estrogen-regulated genes. <i>Breast Cancer Research and Treatment</i> , 1996 , 41, 31-41	4.4	37
319	Biomarkers of dietary energy restriction in women at increased risk of breast cancer. <i>Cancer Prevention Research</i> , 2009 , 2, 720-31	3.2	36
318	A review of the efficacy of anastrozole in postmenopausal women with advanced breast cancer with visceral metastases. <i>Breast Cancer Research and Treatment</i> , 2003 , 82, 215-22	4.4	36
317	The effect of anastrozole on the pharmacokinetics of tamoxifen in post-menopausal women with early breast cancer. <i>British Journal of Cancer</i> , 1999 , 79, 311-5	8.7	36
316	Reverse Warburg effect in a patient with aggressive B-cell lymphoma: is lactic acidosis a paraneoplastic syndrome?. <i>Seminars in Oncology</i> , 2013 , 40, 403-18	5.5	35
315	Static disease on anastrozole provides similar benefit as objective response in patients with advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , 1999 , 58, 157-62	4.4	35
314	Recent advances in endocrine therapy of breast cancer. <i>BMJ: British Medical Journal</i> , 1997 , 315, 863-6		35
313	How to Manage the Obese Patient With Cancer. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4284-4294	2.2	35

312	Risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a 30-year semi-prospective analysis. <i>Familial Cancer</i> , 2015 , 14, 531-8	3	34
311	Breast cancer susceptibility variants alter risks in familial disease. <i>Journal of Medical Genetics</i> , 2010 , 47, 126-31	5.8	34
310	Parathyroid hormone-related protein(50-69) and response to pamidronate therapy for tumour-induced hypercalcaemia. <i>European Journal of Cancer & Clinical Oncology</i> , 1991 , 27, 1629-33		34
309	Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with or at high risk of developing breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012 , 134, 727-34	4.4	33
308	The endocrine prevention of breast cancer. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2008 , 22, 615-23	6.5	33
307	Preventing cancer, cardiovascular disease, and diabetes. <i>Lancet, The</i> , 2005 , 365, 1449-51	40	33
306	Prospective assessment of the role of five tumour markers in breast cancer. <i>Cancer Immunology, Immunotherapy</i> , 1991 , 33, 403-10	7.4	33
305	Downregulation of stromal BRCA1 drives breast cancer tumor growth via upregulation of HIF-1 β autophagy and ketone body production. <i>Cell Cycle</i> , 2012 , 11, 4167-73	4.7	32
304	Polymorphisms of CYP19A1 and response to aromatase inhibitors in metastatic breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2012 , 133, 1191-8	4.4	32
303	Fulvestrant revisited: efficacy and safety of the 500-mg dose. <i>Clinical Breast Cancer</i> , 2011 , 11, 204-10	3	32
302	Acute chemotherapy-related toxicity is not increased in BRCA1 and BRCA2 mutation carriers treated for breast cancer in the United Kingdom. <i>Clinical Cancer Research</i> , 2006 , 12, 7033-8	12.9	32
301	Are aromatase inhibitors superior to antiestrogens?. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2005 , 93, 237-47	5.1	31
300	The effects of oestrogens and anti-oestrogens on cognition. <i>Breast</i> , 2001 , 10, 484-91	3.6	31
299	Infiltrating lobular carcinoma of the breast: response to endocrine therapy and survival. <i>European Journal of Cancer & Clinical Oncology</i> , 1987 , 23, 979-82		31
298	Prognostic Value of a Combined ER, PgR, Ki67, HER2 Immunohistochemical (IHC4) Score and Comparison with the GHI Recurrence Score [Results from TransATAC. 2009 ,		31
297	Breast cancer pathology and stage are better predicted by risk stratification models that include mammographic density and common genetic variants. <i>Breast Cancer Research and Treatment</i> , 2019 , 176, 141-148	4.4	30
296	Sensitivity to further endocrine therapy is retained following progression on first-line fulvestrant. <i>Breast Cancer Research and Treatment</i> , 2005 , 92, 169-74	4.4	30
295	High dose, dose-intensive chemotherapy with doxorubicin and cyclophosphamide for the treatment of advanced breast cancer. <i>British Journal of Cancer</i> , 1993 , 67, 825-9	8.7	30

294	Participant-Reported Symptoms and Their Effect on Long-Term Adherence in the International Breast Cancer Intervention Study I (IBIS I). <i>Journal of Clinical Oncology</i> , 2017 , 35, 2666-2673	2.2	29
293	Estrogen Receptor Expression in 21-Gene Recurrence Score Predicts Increased Late Recurrence for Estrogen-Positive/HER2-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2015 , 21, 2763-70	12.9	29
292	Tumour markers in breast cancer. <i>British Journal of Cancer</i> , 1979 , 40, 710-8	8.7	29
291	Genome-wide association study of germline variants and breast cancer-specific mortality. <i>British Journal of Cancer</i> , 2019 , 120, 647-657	8.7	28
290	Breast cancer: aromatase inhibitors take on tamoxifen. <i>Nature Medicine</i> , 2002 , 8, 1341-4	50.5	28
289	Cancer experience in the relatives of an unselected series of breast cancer patients. <i>British Journal of Cancer</i> , 1994 , 70, 102-11	8.7	28
288	Ethnic entrepreneurship, initial financing, and business performance in China. <i>Small Business Economics</i> , 2019 , 52, 697-712	5.3	28
287	Can the breast screening appointment be used to provide risk assessment and prevention advice?. <i>Breast Cancer Research</i> , 2015 , 17, 84	8.3	27
286	Fulvestrant (Faslodex): current status in the therapy of breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2002 , 2, 151-60	3.5	27
285	Hormonally-regulated proteins in breast secretions are markers of target organ sensitivity. <i>British Journal of Cancer</i> , 2000 , 82, 354-60	8.7	27
284	A protocol for preventative mastectomy in women with an increased lifetime risk of breast cancer. <i>European Journal of Surgical Oncology</i> , 2000 , 26, 711-3	3.6	27
283	Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer. <i>Lancet, The</i> , 1995 , 345, 989-90	40	27
282	Carcinomatous meningitis associated with infiltrating lobular carcinoma of the breast. <i>European Journal of Surgical Oncology</i> , 1985 , 11, 33-6	3.6	27
281	Psychological impact of providing women with personalised 10-year breast cancer risk estimates. <i>British Journal of Cancer</i> , 2018 , 118, 1648-1657	8.7	26
280	Energy restriction and the prevention of breast cancer. <i>Proceedings of the Nutrition Society</i> , 2012 , 71, 263-75	2.9	26
279	Adjuvant aromatase inhibitors for breast cancer. <i>Lancet, The</i> , 2005 , 366, 431-3	40	26
278	New approaches to the endocrine prevention and treatment of breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2003 , 52 Suppl 1, S39-44	3.5	26
277	Serum immunoreactive and bioactive lactogenic hormones in advanced breast cancer patients treated with bromocriptine and octreotide. <i>European Journal of Cancer</i> , 1993 , 29A, 209-17	7.5	26

276	Migration stimulating activity in serum of breast cancer patients. <i>Lancet, The</i> , 1991 , 337, 130-3	4.0	26
275	A comparison of three assays used for the in vitro chemosensitivity testing of human tumours. <i>British Journal of Cancer</i> , 1984 , 49, 57-63	8.7	26
274	Intensive breast screening in BRCA2 mutation carriers is associated with reduced breast cancer specific and all cause mortality. <i>Hereditary Cancer in Clinical Practice</i> , 2016 , 14, 8	2.3	25
273	Lung cancer after treatment for breast cancer. <i>Lancet Oncology, The</i> , 2010 , 11, 1184-92	21.7	25
272	Duration of remission to ICI 182,780 compared to megestrol acetate in tamoxifen resistant breast cancer. <i>Breast</i> , 1997 , 6, 186-189	3.6	25
271	High-throughput genomic technology in research and clinical management of breast cancer. Exploiting the potential of gene expression profiling: is it ready for the clinic?. <i>Breast Cancer Research</i> , 2006 , 8, 214	8.3	25
270	Breast density and breast cancer risk factors in a high-risk population. <i>Breast</i> , 2003 , 12, 10-6	3.6	25
269	Do women understand the odds? Risk perceptions and recall of risk information in women with a family history of breast cancer. <i>Public Health Genomics</i> , 2003 , 6, 214-23	1.9	25
268	Where do selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) now fit into breast cancer treatment algorithms?. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2001 , 79, 227-37	5.1	25
267	The relationship of body weight to response to endocrine therapy, steroid hormone receptors and survival of patients with advanced cancer of the breast. <i>British Journal of Cancer</i> , 1988 , 58, 631-4	8.7	25
266	Prevention of breast cancer in the context of a national breast screening programme. <i>Journal of Internal Medicine</i> , 2012 , 271, 321-30	10.8	24
265	Mechanisms of Disease: prediction and prevention of breast cancer--cellular and molecular interactions. <i>Nature Clinical Practice Oncology</i> , 2005 , 2, 635-46		24
264	Oestrogen sulphotransferases in malignant and normal human breast tissue. <i>Endocrine-Related Cancer</i> , 1995 , 2, 227-233	5.7	24
263	West Midlands Oncology Association trials of adjuvant chemotherapy in operable breast cancer: results after a median follow-up of 7 years. I. Patients with involved axillary lymph nodes. <i>British Journal of Cancer</i> , 1989 , 60, 911-8	8.7	24
262	Reduction in calcium excretion in women with breast cancer and bone metastases using the oral bisphosphonate pamidronate. <i>British Journal of Cancer</i> , 1990 , 61, 123-5	8.7	24
261	Creating a tumor-resistant microenvironment: cell-mediated delivery of TNF α completely prevents breast cancer tumor formation in vivo. <i>Cell Cycle</i> , 2013 , 12, 480-90	4.7	23
260	Breast cancer risk in young women in the national breast screening programme: implications for applying NICE guidelines for additional screening and chemoprevention. <i>Cancer Prevention Research</i> , 2014 , 7, 993-1001	3.2	23
259	The milk protein β -casein functions as a tumor suppressor via activation of STAT1 signaling, effectively preventing breast cancer tumor growth and metastasis. <i>Cell Cycle</i> , 2012 , 11, 3972-82	4.7	23

258	Effect of baseline serum vitamin D levels on aromatase inhibitors induced musculoskeletal symptoms: results from the IBIS-II, chemoprevention study using anastrozole. <i>Breast Cancer Research and Treatment</i> , 2012 , 132, 625-9	4.4	23
257	Energy restriction for breast cancer prevention. <i>Recent Results in Cancer Research</i> , 2009 , 181, 97-111	1.5	23
256	Variation of receptor status in cancer of the breast. <i>British Journal of Cancer</i> , 1983 , 47, 511-5	8.7	23
255	A Randomized Phase-II Study of BB-10010 (Macrophage Inflammatory Protein- 1?) in Patients With Advanced Breast Cancer Receiving 5-Fluorouracil, Adriamycin, and Cyclophosphamide Chemotherapy. <i>Blood</i> , 1998 , 92, 1532-1540	2.2	23
254	Intermittent energy restriction induces changes in breast gene expression and systemic metabolism. <i>Breast Cancer Research</i> , 2016 , 18, 57	8.3	22
253	Anastrozole-Induced Carpal Tunnel Syndrome: Results From the International Breast Cancer Intervention Study II Prevention Trial. <i>Journal of Clinical Oncology</i> , 2016 , 34, 139-43	2.2	22
252	Surveillance of women at increased risk of breast cancer using mammography and clinical breast examination: further evidence of benefit. <i>International Journal of Cancer</i> , 2012 , 131, 417-25	7.5	22
251	Clinical development of fulvestrant ("Faslodex"). <i>Cancer Treatment Reviews</i> , 2005 , 31 Suppl 2, S3-9	14.4	22
250	The clinical value of immunohistochemically demonstrable CEA in breast cancer: a possible method of selecting patients for adjuvant chemotherapy. <i>British Journal of Cancer</i> , 1982 , 46, 757-64	8.7	22
249	Assessment of renal function during high-dose cis-platinum therapy in patients with ovarian carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 1982 , 8, 281-4	3.5	22
248	Predictive classification of human breast carcinomas based on lactalbumin synthesis. <i>Lancet, The</i> , 1977 , 2, 14-6	4.0	22
247	Beliefs about weight and breast cancer: an interview study with high risk women following a 12-month weight loss intervention. <i>Hereditary Cancer in Clinical Practice</i> , 2015 , 13, 1	2.3	21
246	Ovarian cancer among 8,005 women from a breast cancer family history clinic: no increased risk of invasive ovarian cancer in families testing negative for BRCA1 and BRCA2. <i>Journal of Medical Genetics</i> , 2013 , 50, 368-72	5.8	21
245	New developments in the treatment of postmenopausal breast cancer. <i>Trends in Endocrinology and Metabolism</i> , 2005 , 16, 420-8	8.8	21
244	Infusion rate and pharmacokinetics of intravenous pamidronate in the treatment of tumour-induced hypercalcaemia. <i>Postgraduate Medical Journal</i> , 1992 , 68, 434-9	2	21
243	Molecular expression of epitopes recognized by monoclonal antibodies HMFG-1 and HMFG-2 in human breast cancers: diversity, variability and relationship to prognostic factors. <i>International Journal of Cancer</i> , 1986 , 38, 89-96	7.5	21
242	A network analysis to identify mediators of germline-driven differences in breast cancer prognosis. <i>Nature Communications</i> , 2020 , 11, 312	17.4	20
241	Effects of oestrogens and anti-oestrogens on normal breast tissue from women bearing BRCA1 and BRCA2 mutations. <i>British Journal of Cancer</i> , 2006 , 94, 1021-8	8.7	20

240	A cancer research (UK) randomized phase II study of idoxifene in patients with locally advanced/metastatic breast cancer resistant to tamoxifen. <i>Cancer Chemotherapy and Pharmacology</i> , 2004 , 53, 341-8	3.5	20
239	Measurement of urinary collagen cross-links indicate response to therapy in patients with breast cancer and bone metastases. <i>British Journal of Cancer</i> , 1999 , 80, 1265-70	8.7	20
238	Cancer genetics clinics. <i>European Journal of Cancer</i> , 1996 , 32A, 391-2	7.5	20
237	Prognostic relevance of serum hyaluronan levels in patients with breast cancer. <i>International Journal of Cancer</i> , 1992 , 52, 873-6	7.5	20
236	Assessment of four monoclonal antibodies as serum markers in breast cancer. <i>European Journal of Cancer & Clinical Oncology</i> , 1990 , 26, 1127-32		20
235	Low prevalence of HER2 positivity amongst BRCA1 and BRCA2 mutation carriers and in primary BRCA screens. <i>Breast Cancer Research and Treatment</i> , 2016 , 155, 597-601	4.4	19
234	Breast cancer risk assessment in 8,824 women attending a family history evaluation and screening programme. <i>Familial Cancer</i> , 2014 , 13, 189-96	3	19
233	Hormone replacement therapy and breast cancer. <i>Recent Results in Cancer Research</i> , 2011 , 188, 115-24	1.5	19
232	The future of fulvestrant ("Faslodex"). <i>Cancer Treatment Reviews</i> , 2005 , 31 Suppl 2, S26-33	14.4	19
231	Comparative pharmacokinetics of escalating doses of doxorubicin in patients with metastatic breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 1990 , 25, 435-9	3.5	19
230	cis-platinum and ovarian carcinoma. In vitro chemosensitivity of cultured tumour cells from patients receiving high dose cis-platinum as first line treatment. <i>British Journal of Cancer</i> , 1987 , 56, 763-73	8.7	19
229	A case-control evaluation of 143 single nucleotide polymorphisms for breast cancer risk stratification with classical factors and mammographic density. <i>International Journal of Cancer</i> , 2020 , 146, 2122-2129	7.5	19
228	P27(KIP1) expression indicates that steroid receptor-positive cells are a non-proliferating, differentiated subpopulation of the normal human breast epithelium. <i>European Journal of Cancer</i> , 2000 , 36 Suppl 4, S28-9	7.5	18
227	Testosterone and gonadotrophin profiles in patients on daily or monthly LHRH analogue ICI 118630 (Zoladex) compared with orchiectomy. <i>British Journal of Urology</i> , 1986 , 58, 539-44		18
226	A lower incidence of gynecologic adverse events and interventions with anastrozole than with tamoxifen in the ATAC trial. <i>American Journal of Obstetrics and Gynecology</i> , 2009 , 200, 80.e1-7	6.4	17
225	Investigation of mammary epithelial cell-bone marrow stroma interactions using primary human cell culture as a model of metastasis. <i>International Journal of Cancer</i> , 1997 , 73, 690-6	7.5	17
224	Are BRCA1- and BRCA2-related breast cancers associated with increased mortality?. <i>Breast Cancer Research</i> , 2004 , 6, E7	8.3	17
223	Industry relatedness, FDI liberalization and the indigenous innovation process in China. <i>Regional Studies</i> , 2020 , 54, 229-243	3.4	17

222	What are the benefits and harms of risk stratified screening as part of the NHS breast screening Programme? Study protocol for a multi-site non-randomised comparison of BC-predict versus usual screening (NCT04359420). <i>BMC Cancer</i> , 2020 , 20, 570	4.8	16
221	Relationships between CYP2D6 phenotype, breast cancer and hot flushes in women at high risk of breast cancer receiving prophylactic tamoxifen: results from the IBIS-I trial. <i>British Journal of Cancer</i> , 2012 , 107, 230-3	8.7	16
220	ARIMIDEX: a potent and selective aromatase inhibitor for the treatment of advanced breast cancer. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 1997 , 61, 145-149	5.1	16
219	Changes in the normal human breast throughout the menstrual cycle: relevance to breast carcinogenesis. <i>Endocrine-Related Cancer</i> , 1997 , 4, 23-33	5.7	16
218	Personalized prevention in high risk individuals: Managing hormones and beyond. <i>Breast</i> , 2018 , 39, 139-147	3.47	15
217	White Blood Cell BRCA1 Promoter Methylation Status and Ovarian Cancer Risk. <i>Annals of Internal Medicine</i> , 2018 , 168, 326-334	8	15
216	Uptake of breast cancer prevention and screening trials. <i>Journal of Medical Genetics</i> , 2010 , 47, 853-5	5.8	15
215	The emerging breast cancer epidemic: early diagnosis and treatment. <i>Breast Cancer Research</i> , 2010 , 12 Suppl 4, S10	8.3	15
214	Breast tumour stroma is a prognostic indicator and target for therapy. <i>Breast Cancer Research</i> , 2009 , 11 Suppl 3, S16	8.3	15
213	Significant differences in UK and US female bone density reference ranges. <i>Osteoporosis International</i> , 2010 , 21, 1871-80	5.3	15
212	RASSF1A polymorphism in familial breast cancer. <i>Familial Cancer</i> , 2010 , 9, 263-5	3	15
211	Extended role for needle biopsy in the management of carcinoma of the breast. <i>British Journal of Surgery</i> , 1989 , 76, 553-8	5.3	15
210	A new hormonal therapy for prostatic cancer: long-term clinical and hormonal response. <i>British Journal of Urology</i> , 1986 , 58, 534-8		15
209	Hypothesis: persistent expression of fetal phenotypic characteristics by fibroblasts is associated with an increased susceptibility to neoplastic disease. <i>Pathobiology</i> , 1987 , 55, 11-7	3.6	15
208	Automated Breast Tissue Measurement of Women at Increased Risk of Breast Cancer. <i>Lecture Notes in Computer Science</i> , 2006 , 131-136	0.9	15
207	Intermittent energy restriction for weight loss: Spontaneous reduction of energy intake on unrestricted days. <i>Food Science and Nutrition</i> , 2018 , 6, 674-680	3.2	14
206	Long-term prospective clinical follow-up after BRCA1/2 presymptomatic testing: BRCA2 risks higher than in adjusted retrospective studies. <i>Journal of Medical Genetics</i> , 2014 , 51, 573-80	5.8	14
205	Labor Market Segmentation in Urumqi, Xinjiang: Exposing Labor Market Segments and Testing the Relationship between Migration and Segmentation. <i>Growth and Change</i> , 2011 , 42, 200-226	2.3	14

204	Better life expectancy in women with BRCA2 compared with BRCA1 mutations is attributable to lower frequency and later onset of ovarian cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008 , 17, 1535-42	4	14
203	Overview of the impact of conventional systemic therapies on breast cancer. <i>Endocrine-Related Cancer</i> , 2005 , 12 Suppl 1, S9-S16	5.7	14
202	Written report of presented lectures: endocrine treatment and prevention of breast and gynaecological cancers. The scientific basis of endocrine prevention. <i>European Journal of Cancer</i> , 2002 , 38 Suppl 6, S13-4	7.5	14
201	Bisphosphonates and bone metastases. <i>British Journal of Cancer</i> , 1988 , 58, 556-7	8.7	14
200	Combined Associations of a Polygenic Risk Score and Classical Risk Factors With Breast Cancer Risk. <i>Journal of the National Cancer Institute</i> , 2021 , 113, 329-337	9.7	14
199	Preliminary experience with pure antiestrogens. <i>Clinical Cancer Research</i> , 2001 , 7, 4369s-4375s; discussion 4411s-4412s	12.9	14
198	Early participant-reported symptoms as predictors of adherence to anastrozole in the International Breast Cancer Intervention Studies II. <i>Annals of Oncology</i> , 2018 , 29, 504-509	10.3	13
197	Dose-escalating induction chemotherapy supported by lenograstim preceding high-dose consolidation chemotherapy for advanced breast cancer. <i>Annals of Oncology</i> , 1994 , 5, 217-224	10.3	13
196	The synthesis of the glycoprotein hormone alpha subunit by human breast carcinomas. <i>European Journal of Cancer</i> , 1979 , 15, 693-702		13
195	Marshallian Sources of Relatedness and Their Effects on Firm Survival and Subsequent Success in China. <i>Economic Geography</i> , 2017 , 93, 346-366	3.9	12
194	False-negative MRI breast screening in high-risk women. <i>Clinical Radiology</i> , 2017 , 72, 207-216	2.9	12
193	Increased rate of phenocopies in all age groups in BRCA1/BRCA2 mutation kindred, but increased prospective breast cancer risk is confined to BRCA2 mutation carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013 , 22, 2269-76	4	12
192	TPD52 and NFKB1 gene expression levels correlate with G2 chromosomal radiosensitivity in lymphocytes of women with and at risk of hereditary breast cancer. <i>International Journal of Radiation Biology</i> , 2007 , 83, 409-20	2.9	12
191	Heterogeneity of O6-alkylguanine DNA-alkyltransferase expression in human breast tumours. <i>British Journal of Cancer</i> , 2002 , 86, 1797-802	8.7	12
190	Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk. <i>American Journal of Human Genetics</i> , 2020 , 107, 837-848	11	12
189	Risk of Contralateral Breast Cancer in Women with and without Pathogenic Variants in , and Genes in Women with Very Early-Onset (. <i>Cancers</i> , 2020 , 12,	6.6	11
188	Psychosocial issues of a population approach to high genetic risk identification: Behavioural, emotional and informed choice issues. <i>Breast</i> , 2018 , 37, 148-153	3.6	11
187	Mammographic surveillance in women aged 35-39 at enhanced familial risk of breast cancer (FH02). <i>Familial Cancer</i> , 2014 , 13, 13-21	3	11

186	Stromal glycolysis and MCT4 are hallmarks of DCIS progression to invasive breast cancer. <i>Cell Cycle</i> , 2013 , 12, 2935-6	4.7	11
185	Oestrogens, Beatson and endocrine therapy. <i>Endocrine-Related Cancer</i> , 1997 , 4, 371-380	5.7	11
184	Review of recent trials of chemotherapy for advanced breast cancer: studies excluding taxanes. <i>European Journal of Cancer</i> , 1997 , 33, 2171-82	7.5	11
183	A follow-up study of breast and other cancers in families of an unselected series of breast cancer patients. <i>British Journal of Cancer</i> , 2002 , 86, 718-22	8.7	11
182	In situ hybridisation and S1 mapping show that the presence of infiltrating plasma cells is associated with poor prognosis in breast cancer. <i>British Journal of Cancer</i> , 1988 , 58, 715-22	8.7	11
181	Endocrine therapy for advanced carcinoma of the breast: effect of tumor heterogeneity and site of biopsy on the predictive value of progesterone receptor estimations. <i>Cancer Research</i> , 1987 , 47, 296-9	10.1	11
180	Optimal timing of the use of an aromatase inhibitor in the adjuvant treatment of postmenopausal hormone receptor-positive breast cancer. <i>Journal of Clinical Oncology</i> , 2005 , 23, 658-658	2.2	11
179	Heterogeneous impacts of China's economic and development zone program. <i>Journal of Regional Science</i> , 2019 , 59, 797-818	1.8	10
178	A phase II trial of low-dose estradiol in postmenopausal women with advanced breast cancer and acquired resistance to aromatase inhibition. <i>European Journal of Cancer</i> , 2015 , 51, 2725-31	7.5	10
177	Cyclin-dependent kinase inhibitors and basement membrane interact to regulate breast epithelial cell differentiation and acinar morphogenesis. <i>Cell Proliferation</i> , 2007 , 40, 721-40	7.9	10
176	Defining the roles of aromatase inhibitors in the adjuvant treatment of early-stage breast cancer. <i>Clinical Breast Cancer</i> , 2005 , 6, 302-9	3	10
175	The expression of milk fat globule antigens within human mammary tumours: relationship to steroid hormone receptors and response to endocrine treatment. <i>European Journal of Cancer & Clinical Oncology</i> , 1989 , 25, 459-67		10
174	Twenty-four hour combination chemotherapy: a feasibility study with implications for improved adjuvant treatment of breast cancer. <i>European Journal of Cancer & Clinical Oncology</i> , 1983 , 19, 1-4		10
173	Heterogeneity amongst fibroblasts in the production of migration stimulating factor (MSF): implications for cancer pathogenesis. <i>Exs</i> , 1991 , 59, 127-46		10
172	Technological relatedness and asymmetrical firm productivity gains under market reforms in China. <i>Cambridge Journal of Regions, Economy and Society</i> , 2016 , rsw024	3.3	10
171	Breast cancer risk status influences uptake, retention and efficacy of a weight loss programme amongst breast cancer screening attendees: two randomised controlled feasibility trials. <i>BMC Cancer</i> , 2019 , 19, 1089	4.8	10
170	Agglomeration, absorptive capacity and knowledge governance: implications for public-private firm innovation in China. <i>Regional Studies</i> , 2020 , 54, 1069-1083	3.4	10
169	Response and resistance to the endocrine prevention of breast cancer. <i>Advances in Experimental Medicine and Biology</i> , 2008 , 617, 201-11	3.6	10

168	Fetal-like fibroblasts: their production of migration-stimulating factor and role in tumor progression. <i>Cancer Treatment and Research</i> , 1994 , 71, 277-98	3.5	10
167	Future use of selective estrogen receptor modulators and aromatase inhibitors. <i>Clinical Cancer Research</i> , 2001 , 7, 4402s-4410s; discussion 4411s-4412s	12.9	10
166	Breast cancer risk in a screening cohort of Asian and white British/Irish women from Manchester UK. <i>BMC Public Health</i> , 2018 , 18, 178	4.1	9
165	The effectiveness of home versus community-based weight control programmes initiated soon after breast cancer diagnosis: a randomised controlled trial. <i>British Journal of Cancer</i> , 2019 , 121, 443-454	8.7	9
164	Adult weight gain and central obesity in women with and without a family history of breast cancer: a case control study. <i>Familial Cancer</i> , 2007 , 6, 287-94	3	9
163	Re: Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. <i>Journal of the National Cancer Institute</i> , 2006 , 98, 643; author reply 643-4	9.7	9
162	Serum bioactive lactogenic hormone levels in women with familial breast cancer and their relatives. <i>European Journal of Cancer & Clinical Oncology</i> , 1989 , 25, 1719-25		9
161	The primary use of endocrine therapies. <i>Recent Results in Cancer Research</i> , 1998 , 152, 227-44	1.5	9
160	Predictors of weight gain in a cohort of premenopausal early breast cancer patients receiving chemotherapy. <i>Breast</i> , 2019 , 45, 1-6	3.6	9
159	ICI 182,780 (Faslodex) 2000 , 89, 817		9
158	Normal breast tissue implanted into athymic nude mice identifies biomarkers of the effects of human pregnancy levels of estrogen. <i>Cancer Prevention Research</i> , 2009 , 2, 257-64	3.2	8
157	Are we ready for online tools in decision making for BRCA1/2 mutation carriers?. <i>Journal of Clinical Oncology</i> , 2012 , 30, 471-3	2.2	8
156	Effect of early American results on patients in a tamoxifen prevention trial (IBIS). International Breast Cancer Intervention Study. <i>Lancet, The</i> , 1998 , 352, 1222	40	8
155	The 'Arimidex', Tamoxifen, Alone or in Combination (ATAC) Trial: a step forward in the treatment of early breast cancer. <i>Reviews on Recent Clinical Trials</i> , 2006 , 1, 207-15	1.2	8
154	Cost-effectiveness implications of increased survival with anastrozole in the treatment of advanced breast cancer. <i>Journal of Medical Economics</i> , 1999 , 2, 33-43	2.4	8
153	Expression of differentiation antigens within human mammary tumours is related to response to endocrine therapy and survival. <i>International Journal of Cancer</i> , 1988 , 42, 154-8	7.5	8
152	Serum proteins as tumour markers for breast cancer. <i>British Journal of Cancer</i> , 1981 , 43, 542-5	8.7	8
151	The effects of drugs that cause neutropenia upon colony formation by bone marrow cells in semi-solid agar. <i>Clinical Science and Molecular Medicine</i> , 1974 , 46, 619-28		8

150	Tamoxifen as an Agonist for Metastatic Breast Cancer 1990 , 49-58		8
149	The impact of China's R&D subsidies on R&D investment, technological upgrading and economic growth. <i>Technological Forecasting and Social Change</i> , 2022 , 174, 121212	9.5	8
148	Young adulthood body mass index, adult weight gain and breast cancer risk: the PROCAS Study (United Kingdom). <i>British Journal of Cancer</i> , 2020 , 122, 1552-1561	8.7	7
147	Recruitment to the "Breast-Activity and Healthy Eating After Diagnosis" (B-AHEAD) Randomized Controlled Trial. <i>Integrative Cancer Therapies</i> , 2018 , 17, 131-137	3	7
146	A randomised trial of screening with digital breast tomosynthesis plus conventional digital 2D mammography versus 2D mammography alone in younger higher risk women. <i>European Journal of Radiology</i> , 2017 , 94, 133-139	4.7	7
145	A roundtable discussion of aromatase inhibitors as therapy for breast cancer. <i>Breast Journal</i> , 2003 , 9, 213-22	1.2	7
144	Management of women with a family history of breast cancer in the North West Region of England: training for implementing a vision of the future. <i>Journal of Medical Genetics</i> , 2002 , 39, 531-5	5.8	7
143	Mobilisation kinetics of primitive haemopoietic cells following G-CSF with or without chemotherapy for advanced breast cancer. <i>Annals of Oncology</i> , 1996 , 7, 1051-7	10.3	7
142	Clues to the mechanisms of endocrine resistance from clinical studies in advanced breast cancer. <i>Endocrine-Related Cancer</i> , 1995 , 2, 131-139	5.7	7
141	Normal human breast xenografts activate N-nitrosodimethylamine: identification of potential target cells for an environmental nitrosamine. <i>British Journal of Cancer</i> , 1992 , 66, 79-83	8.7	7
140	Risk stratified breast cancer screening: UK healthcare policy decision-making stakeholders' views on a low-risk breast screening pathway. <i>BMC Cancer</i> , 2020 , 20, 680	4.8	7
139	Early stopping of clinical trials. <i>Breast Cancer Research</i> , 2005 , 7, 181-3	8.3	6
138	Is fulvestrant ("Faslodex") just another selective estrogen receptor modulator?. <i>International Journal of Gynecological Cancer</i> , 2006 , 16 Suppl 2, 521-3	3.5	6
137	Tamoxifen withdrawal responses enhance observations or clinical clues to antioestrogen resistance?. <i>Breast</i> , 1994 , 3, 199-201	3.6	6
136	New endocrine approaches to breast cancer. <i>Baillieres Clinical Endocrinology and Metabolism</i> , 1990 , 4, 67-84		6
135	Dibromodulcitol, mitomycin C and vinblastine (DMV) chemotherapy in advanced breast cancer. <i>European Journal of Cancer & Clinical Oncology</i> , 1984 , 20, 873-6		6
134	Estrogen deprivation for breast cancer prevention. <i>Recent Results in Cancer Research</i> , 2007 , 174, 151-67	1.5	6
133	Volumetric and Area-Based Breast Density Measurement in the Predicting Risk of Cancer at Screening (PROCAS) Study. <i>Lecture Notes in Computer Science</i> , 2012 , 228-235	0.9	6

132	Initial results of a study into the effectiveness of breast cancer screening in a population identified to be at high risk. <i>Revue D'Epidemiologie Et De Sante Publique</i> , 2001 , 49, 471-5	0.6	6
131	Final Results of the Prospective FH02 Mammographic Surveillance Study of Women Aged 35-39 at Increased Familial Risk of Breast Cancer. <i>EClinicalMedicine</i> , 2019 , 7, 39-46	11.3	5
130	Breast cancer risk for noncarriers of family-specific BRCA1 and BRCA2 mutations: more trouble with phenocopies. <i>Journal of Clinical Oncology</i> , 2012 , 30, 1142-3; author reply 1143-4	2.2	5
129	The effects of sex steroid replacement therapy on an expanded panel of IGF-related peptides. <i>Growth Hormone and IGF Research</i> , 2007 , 17, 210-9	2	5
128	An early peak of relapse after surgery for breast cancer. <i>Breast Cancer Research</i> , 2004 , 6, 255-7	8.3	5
127	Adjuvant use of anastrozole in breast cancer. <i>Journal of Clinical Oncology</i> , 2004 , 22, 1524-6; author reply 1526-7	2.2	5
126	Models of new antioestrogen action in vivo: primary tumours. <i>Breast</i> , 1996 , 5, 186-191	3.6	5
125	Effect of sodium butyrate on synthesis of specific proteins by human breast-carcinoma cells. <i>British Journal of Cancer</i> , 1980 , 42, 616-9	8.7	5
124	Rapid haematological recovery after high-dose consolidation chemotherapy with peripheral blood progenitor cells (PBPC) as sole source of support collected at a single apheresis. <i>Bone Marrow Transplantation</i> , 1994 , 13, 839-40	4.4	5
123	A linkage study in seven breast cancer families. <i>American Journal of Human Genetics</i> , 1993 , 52, 786-8	11	5
122	Mammographic density change in a cohort of premenopausal women receiving tamoxifen for breast cancer prevention over 5 years. <i>Breast Cancer Research</i> , 2020 , 22, 101	8.3	5
121	Marshallian Sources of Relatedness, Technological Capabilities and Firm Productivity in China. <i>SSRN Electronic Journal</i> , 2016 ,	1	5
120	Minimum wage impacts on Han-minority Workers Wage distribution and inequality in urban china. <i>Journal of Urban Economics</i> , 2020 , 115, 103184	4.1	5
119	The Angelina Jolie effect: Contralateral risk-reducing mastectomy trends in patients at increased risk of breast cancer. <i>Scientific Reports</i> , 2021 , 11, 2847	4.9	5
118	Young age at first pregnancy does protect against early onset breast cancer in BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2018 , 167, 779-785	4.4	5
117	Innovation and Firm Performance in the People's Republic of China: A Structural Approach with Spillovers. <i>SSRN Electronic Journal</i> , 2018 ,	1	5
116	The Systemic Treatment of Bone Metastases 1991 , 121-147		5
115	Relationship of ZNF423 and CTSO with breast cancer risk in two randomised tamoxifen prevention trials. <i>Breast Cancer Research and Treatment</i> , 2016 , 158, 591-6	4.4	4

114	Breast cancer prevention: SERMs come of age. <i>Lancet, The</i> , 2013 , 381, 1795-7	4.0	4
113	Breast cancer susceptibility variants alter risk in familial ovarian cancer. <i>Familial Cancer</i> , 2010 , 9, 503-6	3	4
112	The value of dose intensification of standard chemotherapy for advanced breast cancer using colony-stimulating factors alone. <i>Cancer Treatment Reviews</i> , 1998 , 24, 173-84	14.4	4
111	Pharmacokinetic, biochemical and clinical effects of dimethyltriazenoimidazole-4-carboxamide-bischloroethylnitrosourea combination therapy in patients with advanced breast cancer. <i>International Journal of Cancer</i> , 2003 , 103, 686-92	7.5	4
110	Retroperitoneal tumour infiltration detected by bone scanning in patients with infiltrating lobular carcinoma of the breast. <i>British Journal of Surgery</i> , 1985 , 72, 626-8	5.3	4
109	The therapeutic potential of novel aromatase inhibitors in breast cancer. <i>Expert Opinion on Investigational Drugs</i> , 1999 , 8, 269-79	5.9	4
108	New endocrine treatments for breast cancer: biological and clinical aspects. <i>Breast</i> , 1996 , 5, 170-174	3.6	4
107	Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes.. <i>JAMA Oncology</i> , 2022 ,	13.4	4
106	Cyclical Activity and Ageing of the Human Breast: Clues to Assessment of Risk and Strategies for Prevention 1994 , 27-46		4
105	. <i>Annals of Oncology</i> , 2000 , 11, 255-266	10.3	4
104	Do Marshallian Sources Drive Technological Relatedness? Implications for Firm Survival And Subsequent Success in China. <i>SSRN Electronic Journal</i> , 2016 ,	1	4
103	Uptake of bilateral-risk-reducing-mastectomy: Prospective analysis of 7195 women at high-risk of breast cancer. <i>Breast</i> , 2021 , 60, 45-52	3.6	4
102	Visual assessment of breast density using Visual Analogue Scales: observer variability, reader attributes and reading time 2017 ,		3
101	Can metabolomics in addition to genomics add to prognostic and predictive information in breast cancer?. <i>BMC Medicine</i> , 2010 , 8, 73	11.4	3
100	Strategies for managing breast cancer risk after the menopause. <i>Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders</i> , 2004 , 3, 289-307		3
99	Re: risk-reduction mastectomy: clinical issues and research needs. <i>Journal of the National Cancer Institute</i> , 2002 , 94, 307-8	9.7	3
98	Selective oestrogen receptor downregulator. <i>European Journal of Cancer</i> , 2002 , 38 Suppl 6, S61-2	7.5	3
97	Clinical evidence for the involvement of oestrogen in the development and progression of breast cancer. <i>Proceedings of the Royal Society of Edinburgh Section B Biological Sciences</i> , 1989 , 95, 49-57		3

96	Common variants in breast cancer risk loci predispose to distinct tumor subtypes.. <i>Breast Cancer Research</i> , 2022 , 24, 2	8.3	3
95	Urban Agglomeration, Selection and the Impact of Policy Distortions on Firm Productivity in China. <i>SSRN Electronic Journal</i> ,	1	3
94	High likelihood of actionable pathogenic variant detection in breast cancer genes in women with very early onset breast cancer. <i>Journal of Medical Genetics</i> , 2021 ,	5.8	3
93	'For me it's about not feeling like I'm on a diet': a thematic analysis of women's experiences of an intermittent energy restricted diet to reduce breast cancer risk. <i>Journal of Human Nutrition and Dietetics</i> , 2018 , 31, 773-780	3.1	3
92	The Possible Role of Abnormal Fibroblasts in the Pathogenesis of Breast Cancer 1988 , 142-157		3
91	Macrophage inflammatory protein 1alpha attenuates the toxic effects of temozolomide in human bone marrow granulocyte-macrophage colony-forming cells. <i>Clinical Cancer Research</i> , 2000 , 6, 966-70	12.9	3
90	Lifestyle behaviours and health measures of women at increased risk of breast cancer taking chemoprevention. <i>European Journal of Cancer Prevention</i> , 2019 , 28, 500-506	2	2
89	Picking 'winners' in space: Impact of spatial targeting on firm performance in China. <i>Journal of Regional Science</i> , 2020 , 60, 1025-1046	1.8	2
88	No strong evidence for increased risk of breast cancer 8-26 years after multiple mammograms in their 30s in females at moderate and high familial risk. <i>British Journal of Radiology</i> , 2016 , 89, 20150960	3.4	2
87	PB.17: Inter-observer agreement in visual analogue scale assessment of percentage breast density. <i>Breast Cancer Research</i> , 2013 , 15,	8.3	2
86	Risk algorithms that include pathology adjustment for HER2 amplification need to make further downward adjustments in likelihood scores. <i>Familial Cancer</i> , 2017 , 16, 173-179	3	2
85	Tumour characteristics and survival in familial breast cancer prospectively diagnosed by annual mammography. <i>Breast Cancer Research and Treatment</i> , 2015 , 152, 87-94	4.4	2
84	Local mammographic density as a predictor of breast cancer 2015 ,		2
83	Carbonic anhydrase 9 (CA9) and redox signaling in cancer-associated fibroblasts: therapeutic implications. <i>Cell Cycle</i> , 2013 , 12, 2534-5	4.7	2
82	Same task, same observers, different values: the problem with visual assessment of breast density 2013 ,		2
81	10-year analysis of the ATAC trial: wrong conclusion? [Authors' reply. <i>Lancet Oncology</i> , 2011 , 12, 217	21.7	2
80	Should lifestyle modifications be promoted to prevent breast cancer?. <i>Breast Cancer Research</i> , 2008 , 10 Suppl 4, S11	8.3	2
79	Anastrozole: a new gold standard of hormonal treatment for breast cancer?. <i>Women's Health</i> , 2005 , 1, 309-22	3	2

78	Entry into the tamoxifen prevention trial depends on women's estimates of the population risk of breast cancer. <i>Breast</i> , 1995 , 4, 203-204	3.6	2
77	Should I Take HRT, Doctor?—Hormone Replacement Therapy in Women at Increased Risk of Breast Cancer and in Survivors of the Disease. <i>The Journal of the British Menopause Society</i> , 1995 , 1, 9-17		2
76	Cellular aspects of breast cancer: workshop report. <i>European Journal of Cancer & Clinical Oncology</i> , 1988 , 24, 21-8		2
75	Optimal use of aromatase inhibitors for adjuvant treatment of hormone-sensitive early breast cancer: Up front or sequenced after tamoxifen?. <i>Journal of Clinical Oncology</i> , 2007 , 25, 541-541	2.2	2
74	Minimum Wage Impacts on Inequality, Job Formality and the Ethnic Wage Gap in Urban China. <i>SSRN Electronic Journal</i> ,	1	2
73	Inter-Industry Relatedness, Absorptive Capacity and Firm Productivity in a Transitioning Chinese Economy. <i>SSRN Electronic Journal</i> ,	1	2
72	Growth factor-assisted chemotherapy--the Manchester experience. <i>Novartis Foundation Symposium</i> , 1990 , 148, 201-10; discussion 211-4		2
71	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses		2
70	Long-Term Evaluation of Women Referred to a Breast Cancer Family History Clinic (Manchester UK 1987-2020). <i>Cancers</i> , 2020 , 12,	6.6	2
69	The impact of body mass index on breast cancer incidence among women at increased risk: an observational study from the International Breast Intervention Studies. <i>Breast Cancer Research and Treatment</i> , 2021 , 188, 215-223	4.4	2
68	The Relationship between Body Mass Index and Mammographic Density during a Premenopausal Weight Loss Intervention Study. <i>Cancers</i> , 2021 , 13,	6.6	2
67	Patient reported outcome measures in a cohort of patients at high risk of breast cancer treated by bilateral risk reducing mastectomy and breast reconstruction. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2021 ,	1.7	2
66	RAZOR: A Phase II Open Randomized Trial of Screening Plus Goserelin and Raloxifene Versus Screening Alone in Premenopausal Women at Increased Risk of Breast Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018 , 27, 58-66	4	2
65	Introducing a low-risk breast screening pathway into the NHS Breast Screening Programme: Views from healthcare professionals who are delivering risk-stratified screening. <i>Women's Health</i> , 2021 , 17, 17455065211009746	3	2
64	Code of practice needed for samples donated by trial participants.. <i>Lancet Oncology, The</i> , 2022 , 23, e89-e90		2
63	Explaining the urban premium in Chinese cities and the role of place-based policies. <i>Environment and Planning A</i> , 2020 , 52, 1332-1356	2.7	1
62	Clustering Effects on Firm Exporting with Productivity-Enhancing R&D in China. <i>SSRN Electronic Journal</i> , 2017 ,	1	1
61	Identifying the Sources of Agglomeration Benefits within China's Economic and Development Zones. <i>SSRN Electronic Journal</i> , 2017 ,	1	1

60	Penetrance estimates for , (also applied to Lynch syndrome) based on presymptomatic testing: a new unbiased method to assess risk?. <i>Journal of Medical Genetics</i> , 2018 , 55, 442-448	5.8	1
59	Contralateral breast cancer risk in BRCA1/2-positive families needs to be adjusted for phenocopy rates particularly in second-degree untested relatives. <i>Breast Cancer Research</i> , 2013 , 15, 401	8.3	1
58	Labor Market Segmentation in Urumqi, Xinjiang: Exposing Labor Market Segments and Testing the Relationship between Migration and Segmentation. <i>SSRN Electronic Journal</i> , 2011 ,	1	1
57	Genesis and outcome of a breast cancer trial to develop the aromatase inhibitor anastrozole. <i>Clinical Chemistry</i> , 2012 , 58, 782-3	5.5	1
56	Development of Endocrine Therapy of Breast Cancer 1896 - 2006. <i>Geburtshilfe Und Frauenheilkunde</i> , 2007 , 67, 595-601	2	1
55	Metabolic approaches to breast cancer treatment and prevention. <i>Breast Cancer Research</i> , 2007 , 9,	8.3	1
54	Effect of intermittent versus chronic energy restriction on breast cancer risk biomarkers in premenopausal women: a randomised pilot trial. <i>Breast Cancer Research</i> , 2006 , 8, 1	8.3	1
53	Selective oestrogen receptor modulators, aromatase inhibitors and the female breast. <i>Current Opinion in Obstetrics and Gynecology</i> , 2005 , 17, 429-34	2.4	1
52	Clinical studies with the specific pure antiestrogen ICI 182780. <i>Breast</i> , 1996 , 5, 192-195	3.6	1
51	Release of colony-stimulating activity from the isolated perfused rat liver. <i>Clinical Science and Molecular Medicine</i> , 1976 , 50, 539-44		1
50	A Structural Model of Indigenous Innovation and Catch-Up for Developing Economies. <i>SSRN Electronic Journal</i> ,	1	1
49	Ethnicity, Start-Up Finance, and Entrepreneurship in China. <i>SSRN Electronic Journal</i> ,	1	1
48	Direct and Spillover Effects of Targeted Cash Transfers on Ethnic Rural-Urban Migration in China. <i>SSRN Electronic Journal</i> ,	1	1
47	The origin of estrogen receptor alpha-positive and alpha-negative breast cancer. <i>Advances in Experimental Medicine and Biology</i> , 2008 , 617, 79-86	3.6	1
46	Common variants in breast cancer risk loci predispose to distinct tumor subtypes		1
45	Hormonal Resistance in Breast Cancer. <i>Handbook of Experimental Pharmacology</i> , 1999 , 205-221	3.2	1
44	Picking Winners in China: Do Subsidies Matter for Indigenous Innovation and Firm Productivity?. <i>SSRN Electronic Journal</i> ,	1	1
43	Mammographic Density Over Time in Women With and Without Breast Cancer. <i>Lecture Notes in Computer Science</i> , 2016 , 291-298	0.9	1

42	Use of Volumetric Breast Density Measures for the Prediction of Weight and Body Mass Index. <i>Lecture Notes in Computer Science</i> , 2014 , 282-289	0.9	1
41	Tamoxifen related side effects and their impact on breast cancer incidence: A retrospective analysis of the randomised IBIS-I trial. <i>Breast</i> , 2020 , 54, 216-221	3.6	1
40	Clinical utility of testing for PALB2 and CHEK2 c.1100delC in breast and ovarian cancer. <i>Genetics in Medicine</i> , 2021 , 23, 1969-1976	8.1	1
39	Breast cancer incidence and early diagnosis in a family history risk and prevention clinic: 33-year experience in 14,311 women. <i>Breast Cancer Research and Treatment</i> , 2021 , 189, 677-687	4.4	1
38	Impacts of Migration and Remittances on Ethnic Income Inequality in Rural China. <i>SSRN Electronic Journal</i> , 2016 ,	1	1
37	Off-treatment bone mineral density changes in postmenopausal women receiving anastrozole for 5 years: 7-year results from the IBIS-II prevention trial. <i>British Journal of Cancer</i> , 2021 , 124, 1373-1378	8.7	1
36	Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment. <i>Breast Cancer Research</i> , 2021 , 23, 86	8.3	1
35	Gene Panel Testing for Breast Cancer Reveals Differential Effect of Prior Probability. <i>Cancers</i> , 2021 , 13,	6.6	1
34	The importance of ethnicity: Are breast cancer polygenic risk scores ready for women who are not of White European origin?. <i>International Journal of Cancer</i> , 2022 , 150, 73-79	7.5	1
33	Tamoxifen versus the newer SERMs: what is the evidence?. <i>Annals of Oncology</i> , 2000 , 11 Suppl 3, 255-65	10.3	0
32	Rare germline copy number variants (CNVs) and breast cancer risk.. <i>Communications Biology</i> , 2022 , 5, 65	6.7	0
31	Extending screening intervals for women at low risk of breast cancer: do they find it acceptable?. <i>BMC Cancer</i> , 2021 , 21, 637	4.8	0
30	Testing a breast cancer prevention and a multiple disease prevention weight loss programme amongst women within the UK NHS breast screening programme-a randomised feasibility study.. <i>Pilot and Feasibility Studies</i> , 2021 , 7, 220	1.9	0
29	Does receiving high or low breast cancer risk estimates produce a reduction in subsequent breast cancer screening attendance? Cohort study.. <i>Breast</i> , 2022 , 64, 47-49	3.6	0
28	Breast cancer risks associated with missense variants in breast cancer susceptibility genes.. <i>Genome Medicine</i> , 2022 , 14, 51	14.4	0
27	Clustering effects on firm exporting with productivity-enhancing R&D in China. <i>World Economy</i> , 2019 , 42, 3168-3187	1.7	
26	Reply to Comment on "The effectiveness of home versus community-based weight control programmes initiated soon after breast cancer diagnosis: a randomised controlled trial". <i>British Journal of Cancer</i> , 2020 , 122, 925-926	8.7	
25	The prevention of breast cancer 2018 , 111-128		

- 24 Surgical treatment decisions for older patients: The influence of tumour characteristics, patient health and choice. *Journal of Geriatric Oncology*, **2012**, 3, S19-S20 3.6
- 23 Unerwünschte gynäkologische und operative Interventionen bei der Behandlung des postmenopausalen Mammakarzinoms mit Anastrozol und Tamoxifen. *Geburtshilfe Und Frauenheilkunde*, **2010**, 70, 57-61 2
- 22 Detection and management of women at increased risk of breast cancer. *Clinical Practice (London, England)*, **2012**, 9, 391-401 3
- 21 Development of Endocrine Therapy of Breast Cancer 1896 - 2006. *Senologie - Zeitschrift Für Mammadiagnostik Und -therapie*, **2008**, 5, 50-56 0
- 20 Spreading the word, but not too thinly. *Lancet, The*, **2004**, 363, 165-6 40
- 19 Clarification of anastrozole/megestrol acetate trial program design. *Journal of Clinical Oncology*, **2000**, 18, 4109 2.2
- 18 Failure of long term luteinising hormone releasing hormone treatment for prostatic cancer to suppress serum luteinising hormone and testosterone. *British Medical Journal*, **1984**, 289, 831
- 17 Tumour information from needle biopsy. *Lancet, The*, **1986**, 2, 1342-3 40
- 16 The Use of Milk-Protein Estimation to Assess the Effect of Hormones on Human Breast in Organ Culture. *Clinical Science*, **1979**, 56, 22P-22P 6.5
- 15 An Automated Test for Antigen-Antibody Complexes in Human Sera with a Low-Affinity Igm Antiserum. *Clinical Science*, **1979**, 56, 30P-31P 6.5
- 14 Effect of Altitude on Water Excretion. *Clinical Science*, **1980**, 59, 11P-11P 6.5
- 13 Clinical studies with anastrozole **2008**, 101-125
- 12 Clinical studies with anastrozole **2006**, 95-118
- 11 Estrogen Receptor in Mammary Gland Physiology **2000**, 1-16
- 10 Selective estrogen receptor modulators (SERMs) **2002**, 45-62
- 9 Control of Proliferation in the Normal and Neoplastic Breast **2002**, 73-91
- 8 Incorporating Weight Control into Management of Patients with Early Breast Cancer in the U.K.. *Nutrition and Disease Prevention*, **2005**, 535-560
- 7 The Contribution of Perturbed Epithelial-Mesenchymal Interactions to Cancer Pathogenesis **1992**, 61-72

- 6 A Randomized Phase-II Study of BB-10010 (Macrophage Inflammatory Protein- 1?) in Patients With Advanced Breast Cancer Receiving 5-Fluorouracil, Adriamycin, and Cyclophosphamide Chemotherapy. *Blood*, **1998**, 92, 1532-1540 2.2
- 5 Challenges and Opportunities in the Implementation of Risk-Based Screening for Breast Cancer **2016**, 165-187
- 4 Should We Adjust Visually Assessed Mammographic Density for Observer Variability?. *Lecture Notes in Computer Science*, **2016**, 540-547 0.9
- 3 Endocrine Therapy **2010**, 329-352
- 2 Systemic Treatment and Survival in Carcinoma of the Breast **1986**, 303-312
- 1 Extended gene panel testing in lobular breast cancer. *Familial Cancer*, **2021**, 1 3